Trial · NCT06465264
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
NCT06465264, Phase 3, Completed, Shenzhen Salubris Pharmaceuticals Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil. Trials, record NCT06465264. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06465264
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
- NCT number
- NCT06465264
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 499 participants, actual
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Conditions
- Essential Hypertension
- Interventions
- Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2, Allisartan Isoproxil group 2
- First posted
- 2024-06-18
- Last updated
- 2024-06-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in mean sitting systolic blood pressure after 12 weeks of randomized, double-blind treatment | Baseline, week 12 | Twenty-four hour mean msSBP will be performed at baseline and week 12 of double-blind treatment |
| Secondary | Change from baseline in mean sitting diastolic blood pressure after 12 weeks of randomized, double-blind treatment | Baseline, week 12 | Twenty-four hour mean msDBP will be performed at baseline and week 12 of double-blind treatment |
| Secondary | Change from baseline in mean sitting systolic blood pressure and mean sitting diastolic blood pressure after 4 and 8 weeks of randomized, double-blind treatment | Baseline, week 4, week 8 | Twenty-four hour mean msSBP will be performed at baseline and week 4, week 8 of double-blind treatment |
| Secondary | The proportion of responders to antihypertensive treatment after 12 weeks of randomized, double-blind treatment | Week 12 | Responders is the ratio of the number of participants achieving SBP/DBP\<140/90 mmHg or a reduction from baseline of \>20 mmHg in mean systolic blood pressure and or \>10 mmHg in mean diastolic blood pressure to the total number of participants in each group |
| Secondary | The proportion of patients meeting the mean sitting blood pressure target after 4, 8, and 12 weeks of randomized, double-blind treatment | Week 4, week 8, week 12 | Sitting blood pressure target is SBP/DBP\<140/90 mmHg |
| Other | The proportion of patients meeting the mean sitting blood pressure target after 20 weeks of extended treatment | Week 36 | Sitting blood pressure target is SBP/DBP\<140/90 mmHg |
| Other | The proportion of patients meeting the mean sitting blood pressure target at the end of treatment | Week 56 | Sitting blood pressure target is SBP/DBP\<140/90 mmHg |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39821945 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06465264
GET https://conductscience.org/api/trials/v1/NCT06465264/registered